推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733，021-34243363

chinasupport@letpub.com

登录 注册 新注册优惠

Expert Review of Pharmacoeconomics & Outcomes Research 期刊收藏夹

2026年6月最新影响因子数据已更新，欢迎查询使用。如果您对期刊系统有任何需求或者问题，欢迎点击此处反馈给我们。

期刊名:   ISSN:   研究方向:   IF范围: -   SCI收录:
大类学科:   小类学科:   新锐期刊分区表:   是否OA期刊:   结果排序:
  体验更多LetPub AI科研工具 >>
智能期刊推荐助手

推荐偏好:

  
AI写作痕迹消减工具

 
近期推荐：
热
Wiley 2026暑期线上学习营 | 报名正式开启！
热
多本ABS四星！优质经管国际期刊列表
热
全流程投稿协助套餐服务

按研究方向查看：


Expert Review of Pharmacoeconomics & Outcomes Research期刊基本信息Hello，您是该期刊的第17268位访客


基本信息 登录收藏
期刊名字Expert Review of Pharmacoeconomics & Outcomes ResearchExpert Review of Pharmacoeconomics & Outcomes Research

EXPERT REV PHARM OUT
（此期刊被最新的JCR期刊SCIE收录）

LetPub评分
5.2
51人评分
我要评分

声誉
6.4

影响力
3.8

速度
7.0

期刊ISSN1473-7167
安装APP，查看期刊最新消息
iOS版下载安装安卓版下载安装
E-ISSN1744-8379
2025-2026最新IF
（数据来源于网友提供）		注册或登录后，查看IF
实时影响因子 截止2026年5月06日：2.28
2025-2026自引率4.5%点击查看自引率趋势图
五年IF
（数据来源于网友提供）		2.305数据由网友[憧憬山川]收集提供
h-index 41
CiteScore
（ 2026年6月最新版）
CiteScoreSJRSNIPCiteScore排名
3.400.5110.658
学科分区排名百分位
大类：Medicine
小类：Health Policy		Q2142 / 330
大类：Medicine
小类：Pharmacology (medical)		Q3154 / 278

期刊简介
Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review.

The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections:

Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points.
期刊官方网站http://www.tandfonline.com/toc/ierp20/current
期刊投稿格式模板
VIP专享
Word版格式模板 LaTeX版格式模板
此模板来自于期刊/出版社官网。开通VIP可免费下载，并享1w+期刊模板资源。
此模板来自于期刊/出版社官网。开通VIP可免费下载，并享1w+期刊模板资源。
期刊投稿网址https://mc.manuscriptcentral.com/erp
该期刊中国学者近期发文 - NewEffectiveness and cost-effectiveness of pembrolizumab in persistent, recurrent, or metastatic cervical cancer with PD-L1 CPS 1-10: secondary analysis of KEYNOTE-826 using innovative KMSubtraction
Author: Zhou, Jin; Cai, Jiaqin; Zhang, Lirong; Zhu, Yixiao; Lin, Li; Sun, Hong; Wei, Xiaoxia
Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2026.2688184

Impact of clinical pharmacist-led antimicrobial stewardship on prescribing optimization and economic outcomes in a Chinese county hospital: a retrospective cohort study
Author: Yi, Gao-Yi; Diao, Hong-Mei; Zhou, Qiang; Liu, Xiu-Qiong; He, Yang-Sen
Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2026.2691187

Physicians' preferences for direct-acting antivirals in the treatment of chronic hepatitis C: evidence from a discrete choice experiment in China
Author: Li, Yan; Du, Junni; Tian, Chenhui; Ma, Aixia; Tao, Tiantian; Chen, Pingyu
Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2026.2650162

Cost-effectiveness analysis of rezivertinib and gefitinib in patients with EGFR-mutated advanced non-small cell lung cancer
Author: Kou, Conghui; Wu, Huina; Liu, Lihui; Zhao, Xifeng; Nie, Jing
Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2026.2626573

期刊语言要求经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足Expert Review of Pharmacoeconomics & Outcomes Research的语言要求，还能让Expert Review of Pharmacoeconomics & Outcomes Research编辑和审稿人得到更好的审稿体验，让稿件最大限度地被Expert Review of Pharmacoeconomics & Outcomes Research编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿
是否OA开放访问No
通讯方式2-4 PARK SQUARE, MILTON PARK, ABINGDON, England, OXON, OX14 4RN
出版商Taylor and Francis Ltd.
涉及的研究方向HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY
出版国家或地区ENGLAND
出版语言English
出版周期
出版年份0
年文章数 121点击查看年文章数趋势图
Gold OA文章占比11.59%
研究类文章占比：
文章 ÷（文章 + 综述）		71.07%
期刊分区表预警名单 2026年03月发布的新锐学术版：不在预警名单中

2025年03月发布的2025版：不在预警名单中

2024年02月发布的2024版：不在预警名单中

2023年01月发布的2023版：不在预警名单中

2021年12月发布的2021版：不在预警名单中

2020年12月发布的2020版：不在预警名单中
《新锐期刊分区表》
（ 2026年3月发布） 		点击查看期刊分区表趋势图
大类学科小类学科Top期刊综述期刊
医学 2区4区1区
HEALTH CARE SCIENCES & SERVICES
卫生保健与服务		1区2区4区
HEALTH POLICY & SERVICES
卫生政策与服务		3区1区4区
PHARMACOLOGY & PHARMACY
药学		1区3区4区
否N/A
期刊分区表
（ 2025年3月升级版）
大类学科小类学科Top期刊综述期刊
医学 3区4区2区
HEALTH CARE SCIENCES & SERVICES
卫生保健与服务		3区2区4区
HEALTH POLICY & SERVICES
卫生政策与服务		2区4区4区
PHARMACOLOGY & PHARMACY
药学		4区2区4区
否否
期刊分区表
（ 2023年12月旧的升级版）
大类学科小类学科Top期刊综述期刊
医学 4区4区2区
HEALTH CARE SCIENCES & SERVICES
卫生保健与服务		3区2区4区
HEALTH POLICY & SERVICES
卫生政策与服务		4区2区4区
PHARMACOLOGY & PHARMACY
药学		2区1区4区
否否
SCI期刊收录coverage Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE)
Social Science Citation Index (SSCI)
Scopus (CiteScore)
PubMed Central (PMC)链接http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1473-7167%5BISSN%5D
平均审稿速度网友分享经验：
较慢,6-12周
平均录用比例网友分享经验：
较易
LetPub助力发表经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在Expert Review of Pharmacoeconomics & Outcomes Research顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 。
提交文稿
期刊常用信息链接
同领域相关期刊 Expert Review of Pharmacoeconomics & Outcomes Research期刊近年CiteScore指标趋势图
该杂志的自引率趋势图 Expert Review of Pharmacoeconomics & Outcomes Research期刊分区表趋势图
该杂志的年文章数趋势图 同领域作者分享投稿经验
Expert Review of Pharmacoeconomics & Outcomes Research上中国学者近期发表的论文  
  • 同领域相关期刊
  • 期刊CiteScore趋势图
  • 期刊自引率趋势图
  • 期刊分区表趋势图
  • 年文章数趋势图
  • 该期刊中国学者近期发文
  • 期刊分区表相关期刊
  • 同类著名期刊名称 h-index CiteScore
    International Journal of Nanomedicine10010.60
    Chinese Journal of Natural Medicines277.70
    Chinese Medicine3410.40
    Drug Delivery and Translational Research2714.20
    Drug Design Development and Therapy486.90
    Expert Review of Neurotherapeutics636.30
    Australian Prescriber214.30
    Journal of Global Antimicrobial Resistance166.10
    PEDIATRIC DRUGS557.00
    International Journal for Parasitology-Drugs and Drug Resistance275.80
    期刊分区表同大类学科的热搜期刊 浏览次数
    MEDICINE909128
    JOURNAL OF ETHNOPHARMACOLOGY811667
    Frontiers in Immunology758857
    BIOMEDICINE & PHARMACOTHERAPY732700
    Frontiers in Pharmacology725494
    BIOMATERIALS721853
    PHYTOMEDICINE654287
    Frontiers in Oncology627415
    Biomedical Signal Processing and Control611744
    IEEE Journal of Biomedical and Health Informatics606683
  •  

    Expert Review of Pharmacoeconomics & Outcomes Research Expert Review of Pharmacoeconomics & Outcomes Research
    我来预测明年：
    稳步上升 表现平稳 逐渐下降　 刷新
  •  

    		  
  •  

    		  
  •  

    		  
  • 中国学者近期发表的论文
    1.Effectiveness and cost-effectiveness of pembrolizumab in persistent, recurrent, or metastatic cervical cancer with PD-L1 CPS 1-10: secondary analysis of KEYNOTE-826 using innovative KMSubtraction

    Author: Zhou, Jin; Cai, Jiaqin; Zhang, Lirong; Zhu, Yixiao; Lin, Li; Sun, Hong; Wei, Xiaoxia
    Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2026.2688184        PubMed      DOI
    2.Impact of clinical pharmacist-led antimicrobial stewardship on prescribing optimization and economic outcomes in a Chinese county hospital: a retrospective cohort study

    Author: Yi, Gao-Yi; Diao, Hong-Mei; Zhou, Qiang; Liu, Xiu-Qiong; He, Yang-Sen
    Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2026.2691187        DOI
    3.Physicians' preferences for direct-acting antivirals in the treatment of chronic hepatitis C: evidence from a discrete choice experiment in China

    Author: Li, Yan; Du, Junni; Tian, Chenhui; Ma, Aixia; Tao, Tiantian; Chen, Pingyu
    Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2026.2650162        PubMed      DOI
    4.Cost-effectiveness analysis of rezivertinib and gefitinib in patients with EGFR-mutated advanced non-small cell lung cancer

    Author: Kou, Conghui; Wu, Huina; Liu, Lihui; Zhao, Xifeng; Nie, Jing
    Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2026.2626573        PubMed      DOI
    5.Cost-effectiveness analysis of FOLFOXIRI plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment of metastatic colorectal cancer

    Author: Liu, Tong; Yao, Yao; Liu, Bingjie; Teng, Xue; Dong, Mei; Zhang, Xin
    Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2509706        PubMed      DOI
    6.Cost-effectiveness analysis of sotorasib plus panitumumab in the treatment of refractory colorectal cancer with mutated KRAS G12C in the USA

    Author: Liu, Tong; Yao, Yao; Teng, Xue; Tong, Zhiqiang; Dong, Mei; Yao, Ruihong
    Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2521444        PubMed      DOI
    7.Cost-effectiveness analysis of adagrasib with or without cetuximab in the treatment of colorectal cancer patients with mutated KRAS G12C

    Author: Yao, Ruihong; Yao, Yao; Teng, Xue; Jin, Yao; Guan, Shangwei; Dong, Mei; Liu, Tong
    Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2521439        PubMed      DOI
    8.Cost-effectiveness analysis of Risdiplam and Nusinersen for the treatment of Chinese patients with spinal muscular atrophy

    Author: Huang, Yueyang; Yuan, Hongmei; Huang, Zhe
    Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2499720        PubMed      DOI
    9.Impact of moderate and severe exacerbations on clinical prognosis and economic burden of chronic obstructive pulmonary disease in China

    Author: Gan, Lei; He, Xiaoning; Wu, Jing
    Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2507425        PubMed      DOI
    10.Comprehensive economic value evaluation of adding tislelizumab to first-line chemotherapy for patients with extensive-stage small cell lung cancer in China

    Author: Zhao, Shan; Kang, Shuo
    Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2483423        PubMed      DOI
  • 同大类学科的其他著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144649.80
    LANCET70092.40
    MMWR Surveillance Summaries093.20
    Nature Reviews Clinical Oncology127126.60
    NATURE REVIEWS DRUG DISCOVERY289159.20
    NEW ENGLAND JOURNAL OF MEDICINE93374.80
    Signal Transduction and Targeted Therapy081.60
    ANNALS OF ONCOLOGY21069.60
    Nature Reviews Disease Primers4871.30
    World Psychiatry6184.80
    同分区等级的其他期刊名称 h-index CiteScore
    BRITISH JOURNAL OF BIOMEDICAL SCIENCE4012.70
    Cancer Genetics355.50
    GetMobile-Mobile Computing & Communications Review00.00
    MedComm - Oncology05.30
    Bulletin of the Peabody Museum of Natural History136.80
    Life Medicine06.10
    JBI Evidence Synthesis08.00
    SEMINARS IN ONCOLOGY1254.90
    Turkish Journal of Emergency Medicine05.90
    Cancer Pathogenesis and Therapy06.20
以上SCI期刊相关数据和信息来源于网络，仅供参考。
投稿状态统计： 我要评分：
投稿前担心稿件结构或语言不够规范？试试稿件自查工具，一键检测 >>
与期刊沟通模版下载中心
VIP专享
掌握投稿全流程专业邮件模板，让您的学术沟通高效得体，显著提升论文发表效率！开通VIP可免费下载。
投稿信 (Cover Letter) 模板 回复信 (Response Letter) 模板 投稿状态查询 (Inquiry Letter) 模板
返修延期交稿 (Requesting Extension) 模板 变更作者信息申请 (Author Changes) 模板 拒稿后申诉信 (Appeal Letter) 模板
撤稿申请 (Withdrawal Request Letter) 模板 更正/勘误说明 (Corrigendum/Erratum) 模板 投稿前咨询信 (Pre-submission Inquiry) 模板
没有机构邮箱的说明 (Lack of institutional Email) 模板 更新中...

同领域作者分享投稿经验：共1条

    联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

    © 2010-2026 中国: LetPub上海    网站备案号：沪ICP备10217908号-1    沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）

    增值电信业务经营许可证：沪B2-20211595    网络文化经营许可证：沪网文[2023]2004-152号

    礼翰商务信息咨询（上海）有限公司      办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室